Key takeaways:
- Most contributors achieved IGF-1 management and decreased acromegaly signs at 1 12 months with CAM2029.
- Enhancements in patient-reported outcomes have been additionally reported.
SAN FRANCISCO — Most adults with acromegaly decreased IGF-1 ranges and improved acromegaly signs with once-monthly subcutaneous octreotide depot, in keeping with new analysis.
As Healio beforehand reported, CAM2029 (Camurus) improved IGF-1 and development hormone ranges amongst sufferers with acromegaly in an interim evaluation of the part 3 ACROINNOVA 2 trial. At ENDO 2025, researchers supplied a last evaluation of ACROINNOVA 2 with knowledge from 135 sufferers: 81 who have been enrolled within the trial straight, 36 who obtained CAM2029 within the ACROINNOVA 1 trial and continued into ACROINNOVA 2, and 18 who obtained placebo in ACROINNOVA 1 and began CAM2029 in ACROINNOVA 2.
As soon as-monthly subcutaneous octreotide lowered IGF-1 ranges and obtained excessive satisfaction scores from sufferers with acromegaly in a part 3 trial. Picture: Adobe Inventory
In all three populations, CAM2029 stabilized IGF-1 ranges at or under the higher restrict of regular for many contributors, with no new security considerations.
“What’s actually fascinating is that signs improved repeatedly all through the 52-week remedy,” Joanna L. Spencer-Segal, MD, PhD, medical director of the multidisciplinary pituitary program at College of Michigan Medical College, informed Healio. “The placebo group did not have an enchancment within the signs till they began to [have] biochemical management. … So, there’s improved biochemical management, there’s improved symptom management and the security knowledge look good.”
Joanna L. Spencer-Segal
In ACROINNOVA 2, contributors obtained 20 mg of CAM2029 each 4 weeks for 1 12 months. The first end result was characterization of adversarial occasions. Secondary outcomes included the proportion of contributors with an IGF-1 stage under the higher restrict of regular and alter in Acromegaly Index of Severity rating.
Amongst 127 adults who accomplished the trial, CAM2029 was well-tolerated. Most adversarial occasions have been delicate to reasonable. Injection-site erythema, injection-site swelling and COVID-19 have been the most typical adversarial occasions reported. The one extreme adversarial occasion was one case of cholelithiasis in a affected person assigned placebo in ACROINNOVA 1.
IGF-1 ranges improved
At baseline, 14.8% of contributors who straight enrolled within the trial had an IGF-1 stage at or under the higher restrict of regular. That proportion elevated to 36.5% on the finish of the trial. Amongst contributors who began CAM2029 throughout ACROINNOVA 1 and continued the remedy in ACROINNOVA 2, 88.6% maintained an IGF-1 stage under the higher restrict of regular on the finish of the trial. Amongst adults who have been enrolled within the placebo group in ACROINNOVA 1, 27.8% had an IGF-1 stage at or under the higher restrict of regular once they crossed over into ACROINNOVA 2. On the finish of ACROINNOVA 2, 94.4% have been capable of obtain an IGF-1 stage at or under the higher restrict of regular with CAM2029.
Imply IGF-1 ranges remained steady throughout CAM2029 remedy. Imply Acromegaly Index of Severity rating declined in all teams, and researchers estimated that the proportion of adults with any acromegaly signs declined by 10.9 proportion factors on the finish of the examine vs. baseline.
“These sufferers have been already on customary of care [with] long-acting, first-generation somatostatin receptor ligands and we confirmed that their management may enhance with this treatment,” Spencer-Segal stated. “We predict that is most likely due to the upper bioavailability of octreotide. … So, we will get higher biochemical management and higher symptom management with greater bioavailability of octreotide.”
Excessive remedy satisfaction
CAM2029 is delivered by way of an injection pen, which Spencer-Segal stated gives added comfort for sufferers.
In a second poster introduced at ENDO 2025, researchers assessed patient-reported outcomes in ACROINNOVA 2. Questionnaires assessed included the Acromegaly High quality of Life Questionnaire, Therapy Satisfaction Questionnaire for Remedy and Self-Injection Evaluation Questionnaire.
At 52 weeks, contributors had enhancements in imply complete high quality of life and remedy satisfaction. Ninety-one p.c of contributors stated they have been capable of self-administer the treatment. Satisfaction, self-confidence and emotions about injection scores improved considerably from baseline to the top of the trial.
Diego Ferone, MD, PhD, assistant professor within the endocrinology unit within the division of inside medication at IRCCS Ospedale Policlinico San Martino in Genova, Italy, additionally emphasised the benefit of use with CAM2029’s injection pen.
Diego Ferone
“There’s a clear optimistic report from the sufferers,” Ferone informed Healio. “The system could be very simple to make use of. You don’t have to retailer in refrigeration; you simply want room temperature.”
Ferone added that patient-reported outcomes have been initially a serious focus of the ACROINNOVA 2 trial. He stated the enhancements seen in all of the questionnaires assessed reinforce the potential utility CAM2029 may have for sufferers with acromegaly.
“We hope to supply extra convincing knowledge in regards to the significance of constructing sufferers assured with [their] personal remedy,” Ferone stated.
Reference:
Ferone D, et al. SUN-045. Introduced at: ENDO annual assembly; July 12-15, 2025; San Francisco.
For extra data:
Diego Ferone, MD, PhD, will be reached at diego.ferone@hsanmartino.it.
Joanna L. Spencer-Segal, MD, PhD, will be reached at sjoanna@med.umich.edu.
Sources/Disclosures
Collapse
Spencer-Segal JL, et al. SUN-051. Introduced at: ENDO annual assembly; July 12-15, 2025; San Francisco.
Disclosures:
Ferone stories consulting and receiving analysis help from Camurus AB, Ipsen, Novartis and Recordati. Spencer-Segal stories receiving analysis help from Camurus AB and advising for Camurus AB and Crinetics Prescription drugs.
